SIGN UP
LOG IN
News
PHIO
0.6378
-1.73%
-0.0112
Phio Pharmaceuticals Announces Upcoming Presentations at the 81st Annual Meeting of the Society for Investigative Dermatology (SID)
Phio Pharmaceuticals Corp. Is presenting new data about its lead clinical candidate, PH-762. The data will be presented in three posters at the annual meeting of the Society for Investigative Dermatology in Dallas, Texas. The company's proprietary INTASYL™ gene silencing technology is designed to make immune cells more effective in killing tumor cells.
Barchart · 3d ago
Weekly Report: what happened at PHIO last week (0408-0412)?
Weekly Report · 3d ago
PHIO PHARMACEUTICALS ANNOUNCES UPCOMING PRESENTATION AT THE 27TH ANNUAL MEETING OF THE AMERICAN SOCIETY OF CELL AND GENE THERAPY (ASCGT)
Reuters · 04/11 11:30
Weekly Report: what happened at PHIO last week (0401-0405)?
Weekly Report · 04/08 10:12
National Spotlight Features Phio’s Innovative RNAi Technology Platform
Program will be airing on PBS with Dennis Quaid in April. INTASYL platform will be the focus of Viewpoint. The program will air in April on PBS stations across the country. It will also be seen on Fox Business Network. Phio Pharmaceuticals Corp. Is a clinical stage biotechnology company.
Barchart · 04/03 06:30
Phio Pharmaceuticals on the Brink: Nasdaq Delisting Looms Over Falling Stock Prices
TipRanks · 04/03 06:01
PHIO Stock Earnings: Phio Pharma Beats EPS for Q4 2023
Phio Pharma reported earnings per share of -17 cents for the fourth quarter of 2023. The company did not report any revenue for the quarter. Phio Pharma's results were above the analyst estimate for EPS of -$1.30. The company just reported results for fourth quarter.
Investorplace · 04/02 15:52
Phio Pharmaceuticals GAAP EPS of -$5.20
Phio Pharmaceuticals Corp. Reports FY GAAP EPS of -$5.20. At December 31, 2023 we had cash of $8.5 million as compared to $11.8 million at the end of 2022. The company is expected to report quarterly earnings of $0.02 per share.
Seeking Alpha · 04/02 11:39
*Phio Pharmaceuticals 2023 Loss/Shr $5.20 >PHIO
Dow Jones · 04/02 11:36
PHIO PHARMACEUTICALS REPORTS 2023 YEAR END FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
Reuters · 04/02 11:30
Press Release: Phio Pharmaceuticals Reports 2023 Year End Financial Results and Provides Business Update
Phio Pharmaceuticals Corp. Reports 2023 Year End Financial Results and Provides Business Update. Four sites across the country participating in clinical trial for lead product candidate PH-762. Two patients have already completed treatment for the first cohort. New patent granted for skin related treatments for skin care and skin cancer.
Dow Jones · 04/02 11:30
Press Release: Phio Pharmaceuticals Reports 2023 -2-
Phio Pharmaceuticals Corp. Updates forward-looking statements to reflect a change in its views, events or circumstances that occur after the date of this release. The company's net loss for the quarter ended December 31, 2018 was $11.4 million. The Company's total operating expenses for the year were $10.8 million.
Dow Jones · 04/02 11:30
Weekly Report: what happened at PHIO last week (0325-0329)?
Weekly Report · 04/01 10:11
Phio Pharmaceuticals Corp <PHIO.OQ> expected to post a loss of $1.30 a share - Earnings Preview
Phio Pharmaceuticals Corp expected to post a loss of $1.30 a share - Earnings Preview. The one available analyst rating on the shares is "buy" The company is expected to report results on April 1 for the period ending December 31 2023.
Reuters · 03/29 11:03
Weekly Report: what happened at PHIO last week (0318-0322)?
Weekly Report · 03/25 10:13
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers Biolase (NASDAQ:BIOL) stock rose 20.0% to $0.18 during Thursday's after-market session. The company's market cap increased to $466.4 million. Terns Pharma shares rose 10.14% after their Q4 earnings came out today. Aptevo Therapeutics and Evolus also moved upwards.
Benzinga · 03/21 21:33
12 Health Care Stocks Moving In Thursday's Intraday Session
10 Bioscience (NASDAQ:YTEN) shares moved upwards by 71.5% to $0.42 during Thursday's regular session. Monogram Orthopaedics stock rose 28.74% and X4 Pharmaceuticals stock increased by 21.61%. Tourmaline Bio ( NASDAQ:TRML) shares decreased by 40.6% during the regular session to $26.54.
Benzinga · 03/21 17:31
PHIO and MGRM among healthcare movers
On the Move PHIO and MGRM among healthcare movers. S&P 500 Health Care Sector +0.16% to 1699.95. Pharmaceuticals, Biotechnology & Life Science contributes 58% to index. Nortech Systems and X4 Pharmaceuticals are among the gainers.
Seeking Alpha · 03/21 14:12
Phio Pharmaceuticals Corp <PHIO.OQ> expected to post a loss of $1.30 a share - Earnings Preview
Phio Pharmaceuticals Corp expected to post a loss of $1.30 a share. The one available analyst rating on the shares is "buy" Wall Street's median 12-month price target for the company is $4.00. Phio expected to report results on March 20.
Reuters · 03/18 11:03
Weekly Report: what happened at PHIO last week (0311-0315)?
Weekly Report · 03/18 10:12
More
Webull provides a variety of real-time PHIO stock news. You can receive the latest news about Phio Pharmaceuticals Corp through multiple platforms. This information may help you make smarter investment decisions.
About PHIO
Phio Pharmaceuticals Corp. is a clinical-stage biotechnology company. The Company is focused on developing immuno-oncology therapeutics based on its self-delivering ribonucleic acid interface (RNAi) INTASYL therapeutic platform. Its INTASYL compounds are designed to precisely target specific proteins that reduce the body’s ability to fight cancer without the need for specialized formulations or drug delivery systems, and are designed to make immune cells effective in killing tumor cells. Its lead product candidate, PH-762, is an INTASYL compound designed to reduce the expression of cell death protein 1 (PD-1). PD-1 is a protein that inhibits T cells’ ability to kill cancer cells and is a clinically validated target in immunotherapy. Its second product candidate, PH-894, is an INTASYL compound that is designed to silence BRD4, a protein that controls gene expression in both T cells and tumor cells, thereby effecting the immune system as well as the tumor.